Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans
Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans
复制标题
DOI：
10.1038/s41426-018-0034-0
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Chao Wu
中科院分区：
文献类型：
--
作者：
Chen Tian;Yuxin Chen;Yong Liu;Shixia Wang;Yang Li;Guiyang Wang;Juan Xia;Xiang-an Zhao;Rui Huang;Shan Lu;Chao Wu
Hepatitis B surface antibody (HBsAb) plays a critical role in protecting against infection of hepatitis B virus (HBV) and were extensively studied in literature. At the same time, the status of hepatitis B surface antigen (HBs)-specific B cells in both vaccinated and HBV infected people received limited attention. In the current study, we adopted a highly specific B-cell Enzyme Linked ImmunoSpot (ELISpot) assay to analyze HBs-specific B cells in various clinical settings: healthy individuals with the history of HBV vaccination before and after receiving an extra HBV vaccine boost, people chronically infected with HBV (CHB) in various clinical stages, with or without a particular type anti-viral treatment, or whether receiving a dose of HBV vaccine. In all of these cases, B-cell ELISpot assay was used effectively in enumerating the frequency of HBs-specific B cells. While the focus of the current report was to establish the utility of this assay for HBV research, a number of interesting observations were made in this pilot study based on the profiles and dynamics of HBs-specific B cells in various conditions. Such information is useful to guide the future work in designing novel therapeutic strategies against CHB.
